Publications by authors named "C Guaschino"
Article Synopsis
- COVID-19 vaccines, specifically mRNA types, have been recommended for people with multiple sclerosis (pwMS), and many have received a third booster dose for better immunity.
- A study involving 1265 pwMS investigated the short-term risk of disease reactivation after this booster shot, assessing relapse rates before and after vaccination.
- The results showed no significant increase in relapse rates post-booster (2.1%) compared to the rates before vaccination (1.9%), indicating that the third booster dose is likely safe for pwMS.
Article Synopsis
- A study involving 68 multiple sclerosis patients treated with alemtuzumab tracked the production of T and B lymphocytes over a 48-month period.
- Initially, new T lymphocyte levels dropped significantly three months after treatment, but by 36 months, they peaked, indicating a strong recovery of thymic function.
- B cell production also increased, exceeding baseline levels as soon as three months after starting the treatment, with variations in cellular recovery patterns unrelated to factors like age, sex, previous treatments, or disease outcomes.
Background: Little is known about COVID-19 course and outcomes after a third booster dose of mRNA vaccine against SARS-CoV-2 (mRNA-Vax) in patients with multiple sclerosis (pwMS) treated with ocrelizumab (OCR) and fingolimod (FNG), which showed a weakened immune response to mRNA-vax.
Objectives: The aim of this study was to evaluate COVID-19 course and outcomes in pwMS on OCR and FNG after receiving the third dose of mRNA-Vax and to compare it with pwMS on natalizumab (NTZ).
Methods: Inclusion criteria: >18 years of age, being treated with OCR/FNG/NTZ since the first mRNA-Vax dose; COVID-19 after a third booster dose of mRNA-Vax; no steroids use.
Background: Natalizumab (NAT) has a strong impact on disease activity of aggressive pediatric multiple sclerosis (MS), with no difference in safety profile compared to adult MS. However, available data are limited by short follow-up. Our aim was to report long-term follow-up data (up to 11 years) of a large Italian pediatric MS cohort treated with NAT.
View Article and Find Full Text PDFBackground: Multiple Sclerosis (MS) is a chronic inflammatory and neurodegenerative demyelinating disease of the central nervous system. It is a complex and heterogeneous disease caused by a combination of genetic and environmental factors, and it can cluster in families.
Objective: to evaluate at gene-level the aggregate contribution of predicted damaging low-frequency and rare variants to MS risk in multiplex families.